Healthcare marketing and communications are subject to an increasing number of rules and restrictions, yet in the use of digital channels there is a distinct lack of specific guidance. At Bluelight we have a great deal of experience in crafting online activities that not only comply with the industry specific regulations or codes of practice but also rules and laws in the areas of electronic marketing regulations, data privacy, and accessibility all of which may need to be taken into account.
Compliance Articles
Are health apps medical devices? A white paper from Bluelight & D4
Health professionals make considerable use of mobile phones during their working day, as do their patients. As the popularity of running software applications on mobile devices continues to increase, we anticipate that the use of apps to aid medical diagnosis and treatment will continue to gain in popularity with a corresponding increase in risk to [...]
Should health apps be registered as medical devices? (Press Release)
How safe is that app? Should pharma apps be registered as medical devices? Written by Sam Walmsley and Paul Dixey at Bluelight Partners What impact does the first app to be registered as a medical device with the MHRA have upon pharmaceutical companies and the apps they produce? EMBARGO 8am 10th January 2012 10 January 2012, London – [...]
New ABPI Code of Practice for Pharmaceutical Industry 2012
The ABPI Code of Practice for the Pharmaceutical Industry 2012 is available to download from the PMCPA website. There are no changes from the 2011 Code related to online activities
How to develop and deliver engaging and compliant healthcare digital communications
It is now nearly one year since the PMCPA released Digital Guidelines to go alongside the ABPI Code of Practice. Despite much commentary and repeated requests by many in the pharmaceutical industry it is only the PMCPA in the UK and LIF, the trade association for the research-based pharmaceutical industry in Sweden, that have issued such guidance. It is now over 2 years since the FDA held hearings but have only in December 2011 issued draft guidelines limited to how to respond to unsolicited requests for information about off-label use.
New technologies in healthcare A pre-Digipharm workshop
New technologies in healthcare . A pre-Digipharm workshop to be run by Sam Walmsley of Bluelight